HAD-C 102

General#

Cell Line

hPSCreg Name HADe008-A
Alternative name(s)
HAD-C 102
Cell line type Human embryonic stem cell (hESC)
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Hadassah University Hospital (HAD)
Owner Hadassah University Hospital (HAD)
Distributors
Derivation country Israel

External Databases

Cellosaurus CVCL_B861
NIHhESC NIHhESC-11-0124

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Clinical: allowed
Commercial: allowed

Donor Information#

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Disease associated phenotypes no phenotypes
Family history No known disorders
Is the medical history available upon request? Yes
Is clinical information available? No medical conditions known

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Ethics#

Was the embryo established purely for research purposes? No
Have both parents consented to the use of the embryo for ESC derivation? Yes
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Alternatives to consent are available? Yes
Alternatives to consent Additional info sent separa.
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? IRB
Approval number 33-26-07.02

hESC Derivation#

Date of derivation 2008-12-02
Embryo stage Blastula with ICM and Trophoblast
Supernumerary embryos from IVF treatment?
Yes
Separation of research and IVF treatment?
Yes
PGD Embryo?
No
Expansion status 6
Stephenson 2007
ICM morphology A
Stephenson 2007
Trophectoderm morphology a
Stephenson 2007
Cell isolation Laser
Cell seeding Isolated ICM
Derived under xeno-free conditions?
Yes
Derivation under GMP?
Yes
Available as clinical grade?
Yes

Culture Conditions#

Surface coating Gelatin
Feeder cells umbilical cord fibroblasts
Passage method Enzymatically
TrypLE
O2 Concentration 5 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM
Main protein source: Human Serum
Serum concentration: 20 %

Characterisation#

Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage:

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
XY normal
Karyotyping method: G-Banding

Other Genotyping (Cell Line)